Clinical trial
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic…
NCT00080223 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00080223 |
|---|---|
| Title | Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis |
| Official title | An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis |
| Intervention type | Drug |
| Interventions | Pirfenidone |
| Enrollment | 83 |
| Start date | Aug 31, 2003 |
| Primary completion | Apr 30, 2015 |
| Completion | Apr 30, 2015 |
| First posted | Mar 26, 2004 |
| Last update posted | Apr 17, 2017 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: